What was so great about it? Operating expenses increasing, no milestones in 2014, no mention of the new compounds hinted at in the press release. Dilution is a real possibility to keep the gravy train going.
This latest news, that made this stock pop, seems rather strange. First, in Sep. the company came out with new that the 50mg did not beat the placebo group. The stock begins to drop, insiders sell at the top, and finally the stop drops big.
The 100mg might work, but the tolerability is questionable. I thought a second trial was for the 100mg dose. But, then out comes news, about the safety and effeciency of the 50mg dose. The trial never compared the 50g dose to the placebo controll arm in the last 6 weeks. The 50mg dose,stated earlier in Sep., to not work.
The stock pops 10 pt.. Now, insiders are selling again and analyst are quoteing target prices at $23. What is wrong with this picture. Not to mention, the horrible quarter, and future guideance.
Does anyone know, for any reason why this company is worth more then $6 a share.